Androgen Deprivation Therapy (ADT): clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Androgen Deprivation Therapy (ADT)

• A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
  NCT06320067 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 18 locations
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 692 locations
• A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
  NCT07570979 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 3 locations
• Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
  NCT07237269 · Phase: Phase 2 · Ages: 30 Years and older · Sex: Male · 1 location
• Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
  NCT06772441 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
  NCT06150417 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
  NCT07483658 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 4 locations
• PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
  NCT07426055 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
  NCT07426094 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: Male · 1 location
• Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
  NCT07313241 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
  NCT05790213 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
  NCT07477626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 13 locations
• Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
  NCT05753566 · Phase: Phase 2 · Ages: 40 Years and older · Sex: Male · 2 locations
• Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
  NCT06305832 · Phase: Phase 2 · Ages: 40 Years and older · Sex: Male · 2 locations
• Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer
  NCT07801664 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
  NCT07142967 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location

Common questions

How many recruiting trials involve Androgen Deprivation Therapy (ADT)?

16 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.